Raymond James & Associates’s Universe Pharmaceuticals Inc UPC Stock Holding History

Raymond James & Associates’s Portfolio UPC Stock Details UPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3	Closed	-$30K	–	4283
2021 Q3	$30K	Buy	+3	New	+$27.6K	﹤0.01%	3966

Other funds holding UPC

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Raymond James & Associates's UPC Position: Q4 2021 in Review

Raymond James & Associates sold out of Universe Pharmaceuticals Inc (UPC) in Q4 2021, closing a stake of 3 shares — an estimated $30K sold.

Raymond James & Associates first reported a position in UPC in Q3 2021 and held it in 1 quarter. The position peaked at $30K in Q3 2021. 5 funds tracked by Wall St. Rank hold UPC as of Q4 2021.

Raymond James & Associates reported no remaining Universe Pharmaceuticals Inc position as of Q4 2021 after selling out during the quarter.
Raymond James & Associates sold 3 Universe Pharmaceuticals Inc shares in Q4 2021, an estimated $30K.
Raymond James & Associates first reported a position in Universe Pharmaceuticals Inc in Q3 2021 and held it in 1 quarter.
Raymond James & Associates's Universe Pharmaceuticals Inc position peaked at $30K in Q3 2021.
5 funds tracked by Wall St. Rank held Universe Pharmaceuticals Inc as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.